• Chinese herbal medicine Dengzhan Shengmai capsule as adjunctive treatment for ischemic stroke: A systematic review and meta-analysis of randomized clinical trials 

      Yang, Xiao-Ying; Wang, Li-Qiong; Li, Jin-Gen; Liang, Ning; Wang, Ying; Liu, Jian-Ping (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-12-09)
      <i>Objective</i>: The existing eligible randomized controlled trials (RCTs) were critically appraised for the effectiveness and safety of Chinese herbal medicine Dengzhan Shenmai for ischemic stroke.<p> <p><i>Design</i>: Systematic review and meta-analysis (CRD42016042914, http://www.crd.york.ac.uk/PROSPERO). Methods: Six electronic databases were searched from inception to May 2016. Risk ratio ...
    • Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools 

      Feng, Xiaoshuang; Wu, Wendy Yi-Ying; Onwuka, Justina Ucheojor; Haider, Zahra; Alcala, Karine; Smith-Byrne, Karl; Zahed, Hana; Guida, Florence; Wang, Renwei; Bassett, Julie K.; Stevens, Victoria; Wang, Ying; Weinstein, Stephanie; Freedman, Neal D.; Chen, Chu; Tinker, Lesley; Nøst, Therese Haugdahl; Koh, Woon-Puay; Muller, David; Colorado-Yohar, Sandra M.; Tumino, Rosario; Hung, Rayjean J.; Amos, Christopher I.; Lin, Xihong; Zhang, Xuehong; Arslan, Alan A.; Sánchez, Maria-Jose; Sørgjerd, Elin Pettersen; Severi, Gianluca; Hveem, Kristian; Brennan, Paul; Langhammer, Arnulf; Milne, Roger L.; Yuan, Jian-Min; Melin, Beatrice; Johansson, Mikael; Robbins, Hilary A.; Johansson, Mattias (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-06-01)
      Background: We sought to develop a proteomics-based risk model for lung cancer and evaluate its risk-discriminatory performance in comparison with a smoking-based risk model (PLCOm2012) and a commercially available autoantibody biomarker test.<p><p>Methods: We designed a case-control study nested in 6 prospective cohorts, including 624 lung cancer participants who donated blood samples at most 3 ...